Skip to main content
Annovis Bio, Inc. logo

Annovis Bio, Inc. — Investor Relations & Filings

Ticker · ANVS ISIN · US03615A1088 LEI · 549300IFBVI51FN3NJ32 US Professional, scientific and technical activities
Open in API
Filings indexed 290 across all filing types
Latest filing 2019-08-08 Capital/Financing Update
Country US United States of America
Listing US ANVS

About Annovis Bio, Inc.

https://www.annovisbio.com/

Annovis Bio, Inc. is a clinical-stage drug platform company that develops therapies for neurodegenerative diseases. The company's primary focus is on conditions such as Alzheimer's disease (AD) and Parkinson's disease (PD). Its lead product candidate, buntanetap, is a translational inhibitor designed to halt the death of nerve cells by targeting the synthesis of multiple neurotoxic proteins. The company's therapeutic approach aims to restore nerve cell function, with the goal of improving cognitive and motor abilities in patients suffering from neurodegeneration.

Recent filings

Filing Released Lang Actions
S-1/A
Capital/Financing Update Classification · 95% confidence The document is an Amendment No. 1 to Form S-1 Registration Statement filed with the SEC by Annovis Bio, Inc. It is a registration statement under the Securities Act of 1933, used for initial public offerings (IPOs) or other securities offerings. The text includes details about the offering, underwriting, risk factors, management discussion, and financial data summary. It is not a financial report like an annual or quarterly report, nor is it an earnings release or management discussion standalone. It is a capital markets filing related to the registration and offering of securities. According to the filing definitions, updates on company fundraising or financing activities or capital structure changes fall under Capital/Financing Update (CAP). This S-1/A amendment is part of the capital raising process and thus best classified as CAP. The document length and content confirm it is not a mere announcement but a substantive filing related to capital raising.
2019-08-08 English
Regulatory Filings 2019
Regulatory Filings Classification · 100% confidence The document is a letter from a law firm responding to comments from the SEC staff regarding a Registration Statement on Form S-1 filed by Annovis Bio, Inc. The letter addresses specific comments on the prospectus included in the Registration Statement, including disclosures about clinical trials, risk factors, use of proceeds, and other regulatory compliance matters. The document is not the Registration Statement itself, nor is it a financial report or earnings release. It is a regulatory correspondence responding to SEC comments on a registration filing. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2019-08-08 English
Regulatory Filings 2019
Regulatory Filings Classification · 50% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. Without any discernible information or context, it is impossible to classify this document as any specific filing type. Given the lack of meaningful content, the best classification is the fallback category Regulatory Filings (RNS). The confidence is moderate due to the inability to analyze the content properly.
2019-07-15 English
Regulatory Filings 2019
Regulatory Filings Classification · 95% confidence The document is a detailed response letter from a company (Annovis Bio, Inc.) to the SEC staff comments regarding an Amendment No. 1 to a Draft Registration Statement on Form S-1. The text includes references to the Registration Statement, prospectus disclosures, clinical trial information, risk factors, use of proceeds, and other regulatory compliance details. The document is not the registration statement itself but a comment letter response related to the S-1 filing process. It is a regulatory filing that addresses SEC comments and explains changes made to the registration statement. There is no indication that this is a full annual report, earnings release, or other financial report. It is not a proxy statement or voting results announcement. The document is a regulatory correspondence related to a securities offering registration statement. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2019-07-02 English
S-1
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, which is used for initial public offerings (IPOs) to register securities under the Securities Act of 1933. It includes a preliminary prospectus, details about the offering, risk factors, management discussion, financial data, and underwriting information. This type of filing is neither an annual report, earnings release, nor any other report type listed. It is a capital raising document related to the company's initial public offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, confirming it is not a mere announcement but the actual registration statement/prospectus.
2019-07-02 English
Regulatory Filings 2019
Regulatory Filings Classification · 90% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. Without any meaningful text or context, it is impossible to classify the document as any specific filing type. According to the rules, if a document does not neatly fit into any specific category, it should be classified as a Regulatory Filing (RNS) as a fallback category.
2019-06-21 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.